A randomized, open-label, crossover study examiningthe effect of injection site on bioavailability of exenatide (synthetic exendin-4)
F Calara, K Taylor, J Han, E Zabala, EM Carr… - Clinical …, 2005 - Elsevier
BACKGROUND:: Exenatide (synthetic exendin-4; AC2993) is a 39-amino acid peptide in the
new class of antidiabetic agents known as incretin mimetics. In clinical trials, exenatide
exhibited glucoregulatory effects (glucose-dependent stimulation of insulin secretion,
suppression of inappropriately elevated glucagon secretion, slowing of gastric emptying) in
patients with type 2 diabetes mellitus (DM). OBJECTIVE:: The goal of this study was to
determine the relative bioavailability of exenatide injected subcutaneously into the …
new class of antidiabetic agents known as incretin mimetics. In clinical trials, exenatide
exhibited glucoregulatory effects (glucose-dependent stimulation of insulin secretion,
suppression of inappropriately elevated glucagon secretion, slowing of gastric emptying) in
patients with type 2 diabetes mellitus (DM). OBJECTIVE:: The goal of this study was to
determine the relative bioavailability of exenatide injected subcutaneously into the …